X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human pluripotent stem cells
Therapeutic Area: Neurology Product Name: AstroRx
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 09, 2021
Details:
Kadimastem’s flagship product, AstroRx®, is comprised of a differentiated cell population of human astrocytes derived from human pluripotent stem cells and is in clinical development as a therapeutic treatment for ALS.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human astrocytes
Therapeutic Area: Neurology Product Name: AstroRx
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 15, 2020
Details:
The primary objective of the trial was to evaluate the safety of AstroRx®, an "off-the-shelf", clinical-grade, astrocyte cell product, developed and manufactured by the Company. The trial met its endpoints.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Human astrocytes
Therapeutic Area: Neurology Product Name: AstroRx
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2020
Details:
Kadimastem's lead product, AstroRx®, showed a positive efficacy signal and a good safety profile in Cohort B of the Company’s Phase 1/2a clinical trial in ALS.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): AstroRx
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2020
Details:
A statistically significant decline in disease progression was observed during the first 3- 4 months post-treatment period, indicating a clinical benefit of the AstroRx® cell product.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
